In Section A, participants will get different doses and schedules of oral ABBV-744 tablet to determine safe dosing regimen. More members will probably be enrolled with the discovered monotherapy dosign routine. In Section B, contributors will get oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In Section https://caidenuhvho.bloggactivo.com/31373626/not-known-details-about-brd4-inhibition-by-abbv-744-in-cancer-research-studies